Phase I Trial of the Irreversible EGFR and HER2 Kinase Inhibitor BIBW 2992 in Patients With Advanced Solid Tumors

2010343 citationsJournal Articlebronze Open Access

Authors

Continuous, daily, oral BIBW 2992 is safe and has durable antitumor activity. It is currently being evaluated in phase III trials.

Published in: Journal of Clinical Oncology

Volume 28, Issue 25, pp. 3965-3972

Field-Weighted Citation Impact: 30.63